Zobrazeno 1 - 10
of 89
pro vyhledávání: ''
Autor:
Masaji Tani, Shin-ya Morita, Tomohiro Terada, Naoki Yabuta, Daiki Hira, Hiroya Iida, Masatomo Sudou, Satoshi Noda, Akira Andoh, Yoshinori Wakasugi, Takehide Fujimoto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:281-288
Purpose:We aimed to evaluate exposure-toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC).
Methods:In this retrospective, observational study, 28 HCC patien
Methods:In this retrospective, observational study, 28 HCC patien
Autor:
Satohiro Masuda, Tomoharu Yoshizumi, Masatake Tanaka, Ichiro Ieiri, Yoko Makihara, Motoyuki Kohjima, Kimitaka Suetsugu, Kojiro Hata, Nobuaki Egashira, Hiroyuki Watanabe, Shinji Itoh
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:803-813
This study aimed to examine the association between the trough plasma concentration of lenvatinib with the objective response rate (ORR) and adverse events in patients with hepatocellular carcinoma (HCC). Twenty-one patients with HCC who received len
Autor:
Hiroya Iida, Sachiko Tanaka-Mizuno, Akira Andoh, Takehide Fujimoto, Rie Osaki, Daiki Hira, Satoshi Noda, Masaji Tani, Yoshito Ikeda, Tomohiro Terada, Shin-ya Morita
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:129-139
Purpose:Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharma
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:797-802
To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC).The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015
Autor:
Yoshiki Murakami, Hiroyasu Morikawa, Akihiro Tamori, Masaru Enomoto, Yuga Teranishi, Ayako Iida-Ueno, Le Thi Thanh Thuy, Atsushi Hagihara, Norifumi Kawada, Sawako Uchida-Kobayashi, Hideki Fujii
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:857-864
This study aimed to identify a biomarker for predicting the response to sorafenib in patients with hepatocellular carcinoma (HCC). Of 100 patients with unresectable HCC who received sorafenib treatment in our institute (Cohort A), 48 had stored plasm
Autor:
Norio Ureshino, Takefumi Yoshida, Takayuki Shimose, Tetsuo Tohyama, Hideo Baba, Masahito Kotaka, Tatsuya Kinjo, Hirofumi Kawanaka, Shinichiro Mori, Seiichiro Kai, Hiroshi Saeki, Masaki Mori, Hironori Samura, Koji Ando, Kippei Ohgaki, Yoshihiko Maehara, Kazuma Kobayashi, Akitaka Makiyama, Hiroshi Okumura, Eiji Oki
Publikováno v:
Cancer chemotherapy and pharmacology. 86(2)
This study was designed to assess the tolerability, efficacy, and safety of tri-weekly irinotecan plus S-1 (IRIS) and weekly cetuximab in patients with metastatic colorectal cancer (mCRC). The main eligibility criteria were RAS wild-type mCRC with no
Autor:
Yusuke Hashimoto, Hiroshi Imaoka, Motoyasu Kan, Masafumi Ikeda, Toru Otsuru, Shuichi Mitsunaga, Hideaki Takahashi, Yuko Suzuki, Mitsuhito Sasaki, Kazuo Watanabe, Kyosuke Goda, Izumi Ohno, Kumiko Umemoto, Gen Kimura, Hiroki Eguchi
Publikováno v:
Cancer chemotherapy and pharmacology. 86(2)
Chemotherapy-induced neutropenia (CIN) is a common adverse event of chemotherapy. Several reports have suggested that CIN could be an important prognostic factor in chemotherapy of various cancers. However, whether CIN is a prognostic factor in unres
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:677-684
Sorafenib is a multi-kinase inhibitor for treatment of advanced hepatocellular carcinoma (HCC). Beyond its clinical benefit against advanced HCC, the efficacy and safety of sorafenib chemotherapy are critical concerns. In this study, we addressed the
Autor:
Yixing Jiang, Nathan Bahary, David R. Gandara, John J. Wright, Robert T. O'Donnell, Helen X. Chen, Anthony B. El-Khoueiry, Yun Yen, Thomas J. Semrad, Philip C. Mack, Suzette Blanchard, Heinz-Josef Lenz
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:957-963
PURPOSE: The insulin-like growth factor (IGF) pathway is activated in hepatocarcinogenesis. Cixutumumab is a monoclonal antibody against human insulin-like growth factor-1 receptor (IGF-1R). Given the cross-talk between the IGF and VEGF pathways, we
Autor:
Masataka Ikeda, Kentaro Yamazaki, Takuji Okusaka, A Ohtsu, A Schueler, Toshihiko Doi, M Watanabe
Publikováno v:
Cancer chemotherapy and pharmacology. 84(5)
This study aimed to confirm the recommended phase II dose (RP2D) of pimasertib in Japanese patients. This two-part, phase I dose-escalation and expansion study was conducted in Japanese patients (≥ 18 years old) with advanced solid tumors (ST) incl